Considerations for Creating the Next Generation of RNA Therapeutics: Oligonucleotide Chemistry and Innate Immune Responses to Nucleic Acids

Agrawal S , Christodoulou C and Gait MJ . (1986). Efficient methods for attaching non-radioactive labels to the 5’ ends of synthetic oligodeoxyribonucleotides. Nucleic Acids Res, 14:6227–6245.

Arai H , Emson PC , Agrawal S , Christodoulou C and Gait MJ . (1988). In situ hybridization histochemistry: localisation of vasopressin mRNA in rat brain using a biotinylated oligonucleotide probe. Brain Res, 464:63–69.

Emson PC , Arai H , Agrawal S , Christodoulou C and Gait MJ (1989). Nonradioactive methods of in situ hybridization: visualization of neuroendocrine mRNA. Methods Enzymol, 168:753–761.

Zamecnik PC and Stephenson ML . (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A, 75:280–284.

Stephenson ML and Zamecnik PC (1978). Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A, 75:285–288.

Zamecnik PC , Goodchild J , Taguchi Y and Sarin PS . (1986). Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci U S A, 83:4143–4146.

Miller PS , McParland KB , Jayaraman K and Ts'o PO . (1981). Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry, 20:1874–1880.

Agrawal S and Goodchild J . (1987). Oligodeoxynucleoside methylphosphonates: synthesis and enzymic degradation. Tetrahedron Lett, 28:3539–3542.

Eckstein F. (1985). Nucleoside phosphorothioates. Annu Rev Biochem, 54:367–402.

Goodchild J , Agrawal S , Civeira MP , Sarin PS , Sun D and Zamecnik PC . (1988). Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A, 85:5507–5511.

Sarin PS , Agrawal S , Civeira MP , Goodchild J , Ikeuchi T and Zamecnik PC . (1988). Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates. Proc Natl Acad Sci U S A, 85:7448–7451.

Agrawal S , Goodchild J , Civeira MP , Thornton AH , Sarin PS and Zamecnik PC . (1988). Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A, 85:7079–7083.

Goodchild J , Agrawal S , Sarin PS , Letsinger R and Zamcnik P . (1988). Antisense agents complementary to human immunodeficiency virus. In: Current Communications in Molecular Biology—Antisense RNA and DNA. Melton DA, ed. Cold Spring Harbor, New York, pp. 135–140.

Agrawal S , Ikeuchi T , Sun D , Sarin PS , Konopka A , Maizel J and Zamecnik PC . (1989). Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc Natl Acad Sci U S A, 86:7790–7794.

Lisziewicz J , Sun D , Klotman M , Agrawal S , Zamecnik PC and Gallo RC . (1992). Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc Natl Acad Sci U S A, 89:11209–11213.

Lisziewicz J , Sun D , Metelev V , Zamecnik PC , Gallo RC and Agrawal S . (1993). Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proc Natl Acad Sci U S A, 90:3860–3864.

Leiter JM , Agrawal S , Palese P and Zamecnik PC . (1990). Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci U S A, 87:3430–3434.

Agrawal S , Mayrand SH , Zamecnik PC and Pederson T . (1990). Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides. Proc Natl Acad Sci U S A, 87:1401–1405.

Agrawal S. (1992). Antisense oligonucleotides as antiviral agents. Trends Biotechnol, 10:152–158.

Agrawal S , Temsamani J and Tang JY . (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A, 88:7595–7599.

Agrawal S. (1996). Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 14:. 376–387.

Temsamani J , Tang JY , Padmapriya A , Kubert M and Agrawal S . (1993). Pharmacokinetics, biodistribution, and stability of capped oligodeoxynucleotide phosphorothioates in mice. Antisense Res Dev, 3:277–284.

Zhang R , Diasio RB , Lu Z , Liu T , Jiang Z , Galbraith WM and Agrawal S . (1995). Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol, 49:929–939.

Grindel JM , Musick TJ , Jiang Z , Roskey A and Agrawal S . (1998). Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Antisense Nucleic Acid Drug Dev, 8:43–52.

Zhang R , Yan J , Shahinian HK , Amin G , Lu Z , Liu T , Saag MS , Jiang Z , Temsamani J , et al. (1995). Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther, 58:44–53.

Tang JY , Temsamani J and Agrawal S . (1993) Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity. Nucleic Acids Res, 21:2729–2735.

Agrawal S , Iadarola PL , Temsamani J , Qiuyan Z and Shaw DR . (1996) Effect of G-rich sequences on the synthesis, purification, hybridization, cell uptake, and hemolytic activity of oligonucleotides. Bioorg Med Chem Lett, 6:2219–2224.

Agrawal S , Zhang X , Cai Q , Kandimalla ER , Manning A , Jiang Z , Marcel T and Zhang R . (1998) Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats. J Drug Target, 5:303–312.

Agrawal S , Zhao Q , Jiang Z , Oliver C , Giles H , Heath J and Serota D . (1997). Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev, 7:575–584.

Agrawal S , Rustagi PK and Shaw DR . (1995). Novel enzymatic and immunological responses to oligonucleotides. Toxicol Lett, 82:431–434.

Zhao Q , Temsamani J , Iadarola PL , Jiang Z and Agrawal S . (1996). Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol, 51:173–182.

Galbraith WM , Hobson WC , Giclas PC , Schechter PJ and Agrawal S . (1994). Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev, 4:201–206.

Black LE , Degeorge JJ , Cavagnaro JA , Jordan A and Ahn CH . (1993). Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs. Antisense Res Dev, 3:399–404.

Padmapriya AA , Tang J and Agrawal S . (1994). Large-scale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates. Antisense Res Dev, 4:185–199.

Agrawal S and Tang JY . (1992). GEM 91-an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res Dev, 2:261–266

Agrawal S and Lisziewicz J . (1994). Potential for HIV-1 treatment with antisense oligonucleotides. J Biotech Healthcare, 1:167–182.

Lisziewicz J , Sun D , Weichold FF , Thierry AR , Lusso P , Tang J , Gallo RC and Agrawal S . (1994). Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci U S A, 91:7942–7946.

Agrawal S and Iyer RP . (1995). GEM 91 [Gene Expression Modulator 91]. Drugs Fut, 20:344–351.

Agrawal S. (1995). Antisense oligonucleotide approach for therapy of AIDS. In: Anti-AIDS Drug Development: Challenges, Strategies and Prospects. Mohan P, M Baba, eds. CRC Press, Boca Raton, pp. 143–162.

Agrawal Hybridon S. , Inc. FORM 8- June 29 K , 2000. https://ir.iderapharma.com/node/8761/html (accessed February 25, 2024).

Sereni D , Katlama C , Gouyette A , Ré M , Lascoux C , Tubiana R , and Tournene. C (1994). Phase I study of single intravenous and subcutaneous ascending doses of GEM 91 in HIV positive, asymptomatic volunteers. AIDS, 8:S33.

Agrawal S , Zamecnik M , Sarin PS and Zamecnik PC . (1992). Cellular uptake and anti-HIV activity of oligonucleotide and its analogues. In: Gene Regulation—Biology of Antisense RNA and DNA. Izant JG, RP Erickson, eds. Raven Press, pp. 273–283.

Tang J , Roskey A , Li Y and Agrawal S . (1995). Enzymatic synthesis of stereoregular (all Rp) oligonucleotide phosphorothioate and its properties. Nucleos Nucleot, 14:985–990.

Iyer RP , Guo MJ , Yu D and Agrawal S . (1998). Solid-phase stereoselective synthesis of oligonucleoside phosphorothioates: the nucleoside bicyclic oxazaphospholidines as novel synthons. Tetrahedron Lett, 39:2491–2494.

Yu D , Kandimalla R , Roskey A , Zhao Q , Chen L , Chen J and Agrawal S . (2000). Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties. Bioorg Med Chem, 8:275–284.

Guo M , Yu D , Iye RP , and Agrawal S . (1998). Solid-phase stereoselective synthesis of 2′-O-methyl-oligoribonucleoside phosphorothioates using nucleoside bicyclic oxazaphospholidines. Bioorg Med Chem Lett, 8:2539–2544.

Agrawal S and Kandimalla ER . (2004). Role of toll-like receptors in antisense and siRNA. Nat Biotechnol, 22:1533–1537.

Agrawal S and Kandimalla ER . (2000). Antisense therapeutics: is it as simple as complementary base recognition? Mol Med Today, 6:72–81.

Agrawal S. (1999). Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta, 1489:53–68.

Metelev V , Lisziewicz J and Agrawal S . (1994). Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-o- methyloligoribonucleotides. Bioorg Med Chem Lett, 4:2929–2934.

Yu D , Iyer RP , Shaw DR , Lisziewicz J , Li Y , Jiang Z , Roskey A and Agrawal S . (1996). Hybrid oligonucleotides: synthesis, biophysical properties, stability studies, and biological activity. Bioorg Med Chem, 4:1685–1692.

Temsamani J , Agrawal S and Pederson T . (1991). Biotinylated antisense methylphosphonate oligodeoxynucleotides. Inhibition of spliceosome assembly and affinity selection of U1 and U2small nuclear RNPs. J Biol Chem, 266:468–472.

Sierakowska H , Sambade MJ , Agrawal S and Kole R . (1996). Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci U S A, 93:12840–12844.

Wilton SD , Lloyd F , Carville K , Fletcher S , Honeyman K , Agrawal S and Kole R . (1999). Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord, 9:330–338.

Kandimalla ER , Shaw DR and Agrawal S . (1998). Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotides on human complement and coagulation. Bioorg Med Chem Lett, 8:2103–2108.

Agrawal S , Jiang Z , Zhao Q , Shaw D , Cai Q , Roskey A , Channavajjala L , Saxinger C and Zhang R . (1997). Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci U S A, 94:2620–2625.

Shaw DR , Rustagi PK , Kandimalla ER , Manning AN , Jiang Z and Agrawal S . (1997). Effects of synthetic oligonucleotides on human complement and coagulation. Biochem Pharmacol, 53:1123–1132.

Kandimalla ER , Manning A , Zhao Q , Shaw DR , Byrn RA , Sasisekharan V and Agrawal S . (1997). Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2′-5′-ribo- and 3′-5′-deoxyribonucleotide segments. Nucleic Acids Res, 25:370–378.

Shen LX , Kandimalla ER and Agrawal S. . (1998). Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by Escherichia coli RNase H. Bioorg Med Chem, 6:1695–1705.

Metelev V and Agrawal S . Hybrid oligonucleotide phosphorothioates. https://patents.google.com/patent/US6683167 (accessed February 25, 2024).

Zhou W and Agrawal S . (1998). Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects. Bioorg Med Chem Lett, 8:3269–3274.

Zhang R , Lu Z , Zhao H , Zhang X , Diasio RB , Habus I , Jiang Z , Iyer RP , Yu D and Agrawal S . (1995). In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats. Biochem Pharmacol, 50:545–556.

Agrawal S and Zhao Q . (1998). Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev, 8:135–139.

Agrawal S , Zhang X , Lu Z , Zhao H , Tamburin JM , Yan J , Cai H , Diasio RB , Habus I , et al. (1995). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol, 50:571–576.

Wang H , Cai Q , Zeng X , Yu D , Agrawal S and Zhang R . (1999). Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A, 96:13989–13994.

Agrawal Hybridon S. , Inc. FORM 8-K, May 24, 2001. https://www.sec.gov/Archives/edgar/data/861838/000095013501501616/b39654hye8-k.txt (accessed February 25, 2024).

Geary RS , Baker BF and Monia BP . (2019). Antisense technology: liver targeting and beyond for drug discovery. In: Advances in Nucleic Acid Therapeutics, Agrawal S, MJ Gait, eds. Royal Society of Chemistry, London, pp. 62–79.

Seth PP and Swayze EE . (2019). The medicinal chemistry of RNase H-activating antisense oligonucleotides. In: Advances in Nucleic Acid Therapeutics. Agrawal S, MJ Gait, eds. Royal Society of Chemistry, London, pp. 32–61.

Zhao Q , Temsamani J , Zhou RZ and Agrawal S . (1997). Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev, 7:495–502.

Agrawal S and Iyer RP . (1997). Perspectives in antisense therapeutics. Pharmacol Ther, 76:151–160.

Agrawal S and Martin. RR (2003). Was induction of HIV-1 through TLR9?. J Immunol, 171:1621.

De Clercq E , Eckstein F and Merigan TC . (1969). Interferon induction increased through chemical modification of a synthetic polyribonucleotide. Science, 165:1137–1139.

De Clercq E , Torrence PF and Witkop B . (1974). Interferon induction by synthetic polynucleotides: importance of purine N-7 and strandwise rearrangement. Proc Natl Acad Sci U S A, 71:182–186.

Tokunaga T , Yamamoto H , Shimada S , Abe H , Fukuda T , Fujisawa Y , Furutani Y , Yano O , Kataoka T , et al. (1984). Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical, characterization, and antitumor activity. J Natl Cancer Inst 72:955–962.

Messina JP , Gilkeson GS and Pisetsky DS . (1991). Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol, 147:1759–1764.

Krieg AM , Yi AK , Matson S , Waldschmidt TJ , Bishop GA , Teasdale R , Koretzky GA and Klinman DM . (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374:546–549.

Saitoh SI and Miyake K . (2019). Nucleic acid innate immune receptors. In: Advances in Nucleic Acid Therapeutics. Agrawal S, MJ Gait, eds. Royal Society of Chemistry, London, pp. 292–305.

Zhao Q , Yu D and Agrawal S . (2000). Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorg Med Chem Lett, 10:1051–1054.

Yu D , Kandimalla ER , Zhao Q , Cong Y and Agrawal S . (2001). Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg Med Chem Lett, 11:2263–2267.

Yu D , Kandimalla ER , Zhao Q , Cong Y and Agrawal S . (2001). Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg Med Chem, 9:2803–2808.

Zhao Q , Yu D and Agrawal S . (1999). Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg Med Chem Lett, 9:3453–3458.

Kandimalla ER , Yu D , Zhao Q and Agrawal S . (2001). Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg Med Chem, 9:807–813.

Yu D , Kandimalla ER , Zhao Q , Bhagat L , Cong Y and Agrawal S . (2003). Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA. Bioorg Med Chem, 11:459–464.

Yu D , Zhao Q , Kandimalla ER and Agrawal S . (2000). Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg Med Chem Lett, 10:2585–2588.

Yu D , Kandimalla ER , Zhao Q , Cong Y and Agrawal S . (2002). Immunostimulatory properties of phosphorothioate CpG DNA containing both 3′-5′- and 2′-5′-internucleotide linkages. Nucleic Acids Res, 30:1613–1619.

Kandimalla ER , Bhagat L , Yu D , Cong Y , Tang J and Agrawal S . (2002). Conjugation of ligands at the 5′-end of CpG DNA affects immunostimulatory activity. Bioconjug Chem, 13:966–974.

Putta MR , Bhagat L , Wang D , Zhu FG , Kandimalla ER and Agrawal S . (2013). Immune-stimulatory dinucleotide at the 5′-end of oligodeoxynucleotides is critical for TLR9-mediated immune responses. ACS Med Chem Lett, 4:302–305.

Yu D , Kandimalla ER , Bhagat L , Tang TY , Cong Y , Tang J and Agrawal S . (2002). ‘Immunomers’—novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res, 30:4460–4469.

Yu D , Zhu FG , Bhagat L , Wang H , Kandimalla ER , Zhang R and Agrawal S . (2002). Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun, 297:83–90.

Putta MR , Zhu FG , Wang D , Bhagat L , Dai M , Kandimalla ER and Agrawal S . (2010) Peptide conjugation at the 5′-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity. Bioconjug Chem, 21:39–45.

Kandimalla ER , Bhagat L , Li Y , Yu D , Wang D , Cong Y , Song SS , Tang JX , Sullivan T and Agrawal S . (2005). Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci U S A, 102:6925–6930.

Putta MR , Zhu FG , Li Y , Bhagat L , Cong Y , Kandimalla ER and Agrawal S . (2006). Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications. Nucleic Acids Res, 34:3231–3238.

Yu D , Putta MR , Bhagat L , Li Y , Zhu F , Wang D , Tang JX , Kandimalla ER and Agrawal S . (2007). Agonists of toll-like receptor 9 containing synthetic dinucleotide motifs. J Med Chem, 50:6411–6418.

Yu D , Wang D , Zhu FG , Bhagat L , Dai M , Kandimalla ER and Agrawal S . (2009). Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J Med Chem, 52:5108–5114.

Lan T , Bhagat L , Wang D , Dai M , Kandimalla ER and Agrawal S . (2009). Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8. Bioorg Med Chem Lett, 19:2044–2047.

Lan T , Putta MR , Wang D , Dai M , Yu D , Kandimalla ER and Agrawal S . (2009). Synthetic oligoribonucleotides-containing secondary structures act as agonists of toll-like receptors 7 and 8. Biochem Biophys Res Commun, 386:443–448.

Lan T , Dai M , Wang D , Zhu FG , Kandimalla ER and Agrawal S . (2009). Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies. J Med Chem, 52:6871–6879.

Lan T , Wang D , Bhagat L , Philbin VJ , Yu D , Tang JX , Putta MR , Sullivan T , La Monica N , Kandimalla ER and Agrawal S . (2013). Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune response profiles in vitro and in vivo. Org Biomol Chem, 11:1049–1058.

Yu D , Putta MR , Bhagat L , Dai M , Wang D , Trombino AF , Sullivan T , Kandimalla ER and Agrawal S . (2008). Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction. Antimicrob Agents Chemother, 52:4320–4325.

Agrawal S and Kandimalla ER . (2019). Synthetic agonists of toll-like receptors and therapeutic applications, in advances in nucleic acid therapeutics. In: Advances in Nucleic Acid Therapeutics, Agrawal S and MJ Gait, eds. Royal Society of Chemistry, London, pp. 306–338.

Wang D , Yu D and Agrawal S . (2015). Abstract A56: intratumoral injection of IMO-2055, a novel toll-like receptor 9 agonist, with ipilimumab induces a systemic tumor-specific immune response. Cancer Immunol Res, 3:A56–A56.

Struthers M , Bett AJ , Wisniewski T , Dubey SA , Precopio M , Jiang W , Sun Z , Wang H , Nowak I , et al. (2010). Synthesis and immunological activities of novel agonists of toll-like receptor 9. Cell Immunol, 263:105–113, 2010.

Smith DA , Conkling P , Richards DA , Flores MRC , Nemunaitis JJ , Boyd TE , Mita AC , de La Bourdonnaye G , Wages D and Bexon. AS (2012). Phase 1b study results of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy. Lung Cancer, 77:S39.

Smith DA , Conkling P , Richards DA , Nemunaitis JJ , Boyd TE , Mita AC , de La Bourdonnaye G , Wages D and Bexon AS . (2014). Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy. Cancer Immunol Immunother, 63:787–796.

Ruzsa A , Sen M , Evans M , Lee LW , Hideghety K , Rottey S , Klimak P , Holeckova P , Fayette J , et al. (2014). Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Invest New Drugs, 32:1278–1284.

Haymaker C , Johnson DH , Murthy R , Bentebibel SE , Uemura MI , Hudgens CW , Safa H , James M , Andtbacka RHI , et al. (2021). Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov, 11:1996–2013.

Kandimalla ER , Bhagat L , Wang D , Yu D , Sullivan T , La Monica N and Agrawal S . (2013). Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res, 41:3947–3961.

Wang D , Bhagat L , Yu D , Zhu FG , Tang JX , Kandimalla ER and Agrawal S . (2009). Oligodeoxyribonucleotide-based antagonists for toll-like receptors 7 and 9. J Med Chem, 52:551–558.

Jiang W , Zhu FG , Bhagat L , Yu D , Tang JX , Kandimalla ER , La Monica N and Agrawal S . (2013). A toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol, 133:1777–1784.

Zhu FG , Jiang W , Bhagat L , Wang D , Yu D , Tang JX , Kandimalla ER , La Monica N and Agrawal S . (2013). A novel antagonist of toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice. Autoimmunity, 46:419–428.

Henriques-Pons A , Yu Q , Rayavarapu S , Cohen TV , Ampong B , Cha HJ , Jahnke V , Van der Meulen J , Wang D , et al. (2014). Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. Hum Mol Genet, 23:2604–2617.

Zhu F , Wang D , Jiang W , Bhagat L and Agrawal S . (2015). Targeting innate immune receptors to treat inflammatory bowel disease: preclinical activity of IMO-9200, an antagonist of TLRS 7, 8, and 9 in mouse models of colitis. Gastroenterology, 148:S-324.

Bhagat L. , Wang D , Jiang W and Agrawal S. . (2014). Abstract 2570: IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88L265P mutation-driven signaling and cell survival: a potential novel approach for treatment of B-cell lymphomas harboring MYD88L265P mutation. Cancer Res, 74:2570.

Idera Pharmaceuticals. Trial of IMO-3100 in patients with moderate to severe plaque psoriasis. https://www.clinicaltrials.gov/ct2/show/NCT01622348 (accessed February 25, 2024).

Idera Pharmaceuticals. Extension study of IMO-8400 in patients with Waldenström's macroglobulinemia who completed study 8400-401. https://classic.clinicaltrials.gov/ct2/show/NCT02363439 (accessed February 25, 2024).

Bhagat L , Putta MR , Wang D , Yu D , Lan T , Jiang W , Sun Z , Wang H , Tang JX , et al. Novel oligonucleotides containing two 3′-ends complementary to target mRNA show optimal gene-silencing activity. J Med Chem, 54:3027–3036.

Gait MJ and Agrawal S . (2022). Introduction and history of the chemistry of nucleic acids therapeutics. In: Antisense RNA Design, Delivery, and Analysis. Arechavala-Gomeza V, A Garanto, eds. Springer, New York, pp. 3–31.

Agrawal S and Gait MJ . (2019). History and development of nucleotide analogues. In: Advances in Nucleic Acid Therapeutics. Agrawal S, MJ Gait, eds. Royal Society of Chemistry, London, pp. 1–21.

Agrawal S . (2021). The evolution of antisense oligonucleotide chemistry—a personal journey. Biomedicines, 9:503.

Agrawal WO S. /2020/191177—Antisense oligonucleotides for allele specificity. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020191177 (accessed February 25, 2024).

Agrawal WO S. /2021/055011—compounds and methods useful for modulating gene splicing. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021055011&_cid=P10-LT4JVI-47040-1 (accessed February 25, 2024).

Agrawal WO S. /2023/049275—cyclic structured oligonucleotides as therapeutic agents. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023049275&_cid=P10-LT4JXL-48950-1 (accessed February 25, 2024).